Abstract
The Substance Abuse and Mental Health Services Administration (SAMHSA), which regulates opioid treatment programs (OTPs), buprenorphine prescribing, and funds the block grant for publicly funded treatment for substance use disorders (SUDs) has called on providers to make treatment easier to access. In SAMHSA's “Advisory: Low Barrier Models of Care for Substance Use Disorders,” released quietly on Dec. 8, the federal agency said research proves that “low barrier” care — a phrase from advocates who wanted fewer restrictions to buprenorphine (most of which have now been removed) — is effective. The document calls patients “clients” (most of the time), and cites research supporting bridge clinics, syringe services programs, and “culturally responsive and trauma‐informed care.” Although the advisory is not limited to opioids, much of the content, and references, are, with a special focus on buprenorphine. Mutual support organizations like Alcoholics Anonymous, which is free, are not mentioned.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
